Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
about
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsIL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasmsThe PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.JAK/STAT regulation of Aspergillus fumigatus corneal infections and IL-6/23-stimulated neutrophil, IL-17, elastase, and MMP9 activity.Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines.Kinase signaling and targeted therapy for primary myelofibrosis.Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Posttreatment Megakaryocytic Hyperplasia with JAK-2 Mutation.Novel Therapies for Myelofibrosis.Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway.
P2860
Q26782539-D3425457-2410-428A-A626-A3744BF1A5E6Q36040193-3518FCDF-DF1C-4292-9A7E-6630F307C35BQ36545566-498501E3-5394-4710-ACAE-042697D05BEDQ37098061-E3B8C2AC-8358-4E8E-9BE4-1D1C7AB61223Q37392623-A7BD05BF-646D-4757-8383-49F0D3D1FECEQ38775472-973C148E-CBCD-4598-BD22-B56C1AA85F82Q41379688-38C0C5E5-522A-4316-94CE-3256D935CFA8Q52817185-F88C19A3-2AEE-4CA4-8D91-DA7FAE491252Q55042835-D2E925F9-6E6B-4405-8584-E816BD867E11
P2860
Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
@en
type
label
Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
@en
prefLabel
Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
@en
P2093
P2860
P1476
Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
@en
P2093
Neha Bhagwat
Priya Koppikar
Ross L Levine
P2860
P2888
P304
P356
10.1007/S12185-013-1353-5
P577
2013-05-14T00:00:00Z
P5875
P6179
1052190754